CAR-T cell therapy uses a patient’s own T cells that are collected, genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells, and then expanded and reinfused after a brief period of lymphodepleting chemotherapy. This engineered receptor lets the T cells recognize and kill malignant B cells with high specificity. CD19 is a common target because it is present on most B-lineage cells, including many malignant ones, making this approach effective across several B-cell cancers. The approved indications reflect its use in relapsed or refractory B-cell acute lymphoblastic leukemia and certain relapsed/refractory B-cell lymphomas after other therapies have failed. It is not a standard treatment for acute myeloid leukemia, chronic lymphocytic leukemia, or other non-B-cell malignancies, and it differs from monoclonal antibody therapies against CD20, which are non-genetic antibody-based approaches rather than T cells engineered to attack the cancer. While most approved CAR-T products use autologous T cells, research into allogeneic CAR-T and other cell types like NK cells is ongoing.

Hemophilia is a deficiency of intrinsic pathway coagulation factors (such as factor VIII or IX). The test that reflects this pathway is the partial thromboplastin time (PTT), so when intrinsic factors are lacking, the PTT is prolonged. Platelet count remains normal because platelets and primary hemostasis are not the primary problem in hemophilia, and white blood cell count is not affected by this bleeding disorder. Hemoglobin might decrease with ongoing bleeding, but that is a secondary effect rather than a diagnostic feature. Therefore, the abnormal lab finding you’d expect is an increased PTT.

Stress can trigger a sickle cell crisis because emotional or physical stress activates the sympathetic system, raising metabolic demands and often causing vasoconstriction and relative tissue hypoxia. This combination promotes deoxygenation of hemoglobin S, encouraging its polymerization, which makes red cells rigid and prone to clog small vessels, leading to a vaso-occlusive crisis. Dehydration, infection, and low oxygen levels are classic triggers, while fluid overload doesn’t directly promote sickling, insomnia isn’t a direct precipitant, and sticking with treatment for infections (antibiotics) helps prevent crises rather than precipitating them.

Splenic sequestration crisis occurs when the spleen suddenly traps a large volume of red blood cells, causing a rapid drop in hemoglobin and potential shock. The goal is to stop the sequestration and prevent recurrence. Splenectomy is a treatment option for patients with recurrent or severe episodes because removing the spleen eliminates the primary site where blood pooling happens, reducing the risk of future crises. The other choices don’t address the underlying problem: antibiotics alone don’t fix the sequestration since it isn’t an infection; doing nothing isn’t safe in a crisis; iron chelation therapy treats iron overload from transfusions, not the acute sequestration.